Plan to Cure All Disease by 2100

Your daily digest on longevity, investment, science & lifestyle ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ November 8th, 2023 | [Read Online]( Join us at the premier longevity event, held in Miami from November 9th-11th. Use the link below to receive a 20% discount on tickets. Good Morning , In this digest, we delve into ambitious initiatives and breakthroughs that exemplify the relentless pursuit of longevity research that we are seeing unfold. From the audacious vision of the Chan Zuckerberg Initiative, redefining goals to master cell behavior for combating diseases, to the celebration of trailblazers awarded the 2024 Breakthrough Prizes for transforming the treatment of cystic fibrosis and leukemia, we highlight the leaps made towards conquering life-limiting conditions. And beyond the pond, British biotech's stride into the longevity arena showcases the immense potential and hurdles in translating aging research into real-world therapies, aiming to pivot healthcare towards treating the underlying processes of aging rather than its symptoms. Join us as we uncover the dynamic interplay of technology, dedication, and vision propelling us towards a future where the zenith of health is within reach. To 2100 … EVERY WEDNESDAY Research Round-up Mark Zuckerberg and Dr. Priscilla Chan’s plan to prevent and cure all diseases by 2100 In a recent Fortune interview, Dr. Priscilla Chan (and ultimately Mark Zuckerberg through the Chan Zuckerberg Initiative (CZI)) shared insights into their revised decade-long goal: to deeply understand cell behavior in health and disease states. Initially aiming to cure or manage all diseases by 2100, CZI now focuses on cellular research, a critical piece of the puzzle in tackling diseases, according to Chan. CZI's work shines at the intersection of health equity and rare diseases, recognizing that while individual rare diseases are uncommon, they affect 1 in 10 people globally. These patients often experience a diagnostic odyssey fraught with misdirection and denial, especially in under-resourced areas. Through collaborations with rare disease groups, CZI aspires to quicken and democratize the path to diagnosis and treatment, leveraging their resources for a profound impact on patient outcomes. [Fortune]( The most striking discovery was in the elderly, where taurine levels were a staggering 80% lower than in their younger counterparts. This nutrient's potential seems promising, especially when considering its ability to add an estimated seven to eight years to human life. Cystic Fibrosis Pioneers Awarded $3 Million The 2024 Breakthrough Prizes have celebrated significant medical science advancements. Vertex Pharmaceuticals' researchers, led by Dr. Fredrick van Goor, were recognized with $3 million for developing Trikafta, a drug transforming cystic fibrosis treatment for over 90% of patients. Similarly honored were Carl June and Michel Sadelain, who innovated CAR-T immunotherapy for leukemia, a technique now extending to various cancers. Thomas Gasser, Ellen Sidransky, and Andrew Singleton's work, which has deepened understanding of Parkinson's disease genetics, was also awarded. Funded by an alliance of science and tech philanthropists, these awards underscore the relentless progress in medical science, signifying a leap forward in treating complex, life-altering diseases. [Forbes]( Epidemiological observations have long hinted at a curious phenomenon: populations residing at high altitudes often live longer and seem less susceptible to certain diseases. This study sought to replicate these findings in a controlled animal setting, shedding light on the potential benefits of high-altitude living. British Biotech Races US’s ‘Buff Billionaires’ In the UK, a King’s College study on avid cyclists between 55 and 79 unveiled that consistent exercise might stave off common age-related declines in muscle, bone density, and immune function. This insight is a cornerstone in Britain's emerging role in the lucrative longevity research sector, projected to hit $2bn by 2030. British biotech startups are pioneering alongside US counterparts, developing therapies aimed at extending healthspan. Yet, despite groundbreaking research, the UK lags in translating science into ventures, hindered by a deficit in entrepreneurial training and venture capital. The focus now shifts towards cellular rejuvenation and combatting inflammation, crucial factors in biological ageing. This approach promises a healthcare revolution, treating ageing's root causes rather than its diseases, positioning the UK at the forefront of this global transformation. [The Guardian]( Sima, the last surviving rat from the study, stands as a testament to the treatment's potential. She has already surpassed the typical lifespan for her species, drawing parallels to a human living beyond 126 years. In this edition of our weekly digest, we've witnessed remarkable strides across the globe that exemplify the growing momentum in longevity research. From the Chan Zuckerberg Initiative's refocused mission to comprehend cellular behaviors to the breakthrough innovations celebrated by the Breakthrough Prizes, each narrative presents a tile in the mosaic of medical advancement. The recognition of pioneering treatments for cystic fibrosis and leukemia, alongside the UK's push into the biology of aging, underscores a shift towards proactive, preventative, and personalized medicine. These stories serve as a testament to the scientific community's dedication to unraveling the complex tapestry of longevity, propelling us closer to a future where the full spectrum of human health is not just envisioned but achieved. Here’s to eradicating treatable disease, The Longr Reads Team "Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less." Marie Curie, Researcher Longr Reads' of the Week - Forward Thinking on how to live our longer lives with Andrew J. Scott ([McKinsey]( - Andrew Huberman w/ Dr. David Sinclair: The Biology of Slowing & Reversing Aging ([Youtube]( - The Economics of Longevity - An Introduction ([ScienceDirect]( Longr is building access to longevity across: generative AI, therapeutics, wellness products, clinics, research, community, and marketplaces. Transforming visionary concepts into tangible solutions - we are facilitating widespread adoption of longevity-enhancing products and platforms. [Advertise with us](mailto:partnerships@longr.io) // [Book a call with Longr](mailto:ir@longr.io) 107 North Orange Street, Wilmington, Delaware 19801, United States You received this email from Longr Reads. If you would like to unsubscribe, [click here](.